benign prostatic hyperplasia	is a	urological condition
benign prostatic hyperplasia	causes	lower urinary tract symptoms
benign prostatic hyperplasia	leads to	urinary retention
benign prostatic hyperplasia	causes	bladder outlet obstruction
benign prostatic hyperplasia	associated with	nocturia
benign prostatic hyperplasia	associated with	urinary urgency
benign prostatic hyperplasia	associated with	hesitancy
benign prostatic hyperplasia	associated with	weak stream
benign prostatic hyperplasia	associated with	incomplete bladder emptying
benign prostatic hyperplasia	increases risk of	urinary tract infection
benign prostatic hyperplasia	increases risk of	hydronephrosis
benign prostatic hyperplasia	increases risk of	renal impairment
benign prostatic hyperplasia	diagnosed by	digital rectal examination
benign prostatic hyperplasia	diagnosed with	transrectal ultrasound
benign prostatic hyperplasia	evaluated with	PSA testing
benign prostatic hyperplasia	evaluated with	urinalysis
benign prostatic hyperplasia	managed with	alpha-1 blocker
benign prostatic hyperplasia	managed with	5-alpha-reductase inhibitor
finasteride	is a	5-alpha-reductase inhibitor
dutasteride	is a	5-alpha-reductase inhibitor
tamsulosin	is a	alpha-1A selective blocker
alfuzosin	is a	alpha-1 blocker
silodosin	is a	alpha-1A selective blocker
benign prostatic hyperplasia	treated with	combination therapy
benign prostatic hyperplasia	treated with	surgery
transurethral resection of the prostate	is a	surgical procedure
UroLift	is a	minimally invasive procedure
Rezum therapy	is a	minimally invasive procedure
antibiotics	used for	urinary tract infection associated with BPH
aging	is a	risk factor for benign prostatic hyperplasia
obesity	is a	risk factor for benign prostatic hyperplasia
metabolic syndrome	is a	risk factor for benign prostatic hyperplasia
diabetes mellitus	is a	risk factor for benign prostatic hyperplasia
family history	increases risk of	benign prostatic hyperplasia
benign prostatic hyperplasia	associated with	increased prostate volume
bladder outlet obstruction	causes	detrusor hypertrophy
detrusor hypertrophy	results from	bladder outlet obstruction
hydronephrosis	can occur	due to prostatic obstruction
renal impairment	can develop	from chronic obstruction
post-void residual	is a	measure of bladder emptying
maximal urinary flow rate	is a	measure of urinary outflow
urodynamic study	is a	diagnostic test
Qmax	is a	measure of urinary outflow
watchful waiting	is an option for	mild symptoms
lifestyle modification	used for	mild symptoms of BPH
UroLift	preserves	sexual function
UroLift	reduces	prostatic obstruction
UroLift	results in	symptom relief
symptom relief	improves	quality of life
TURP	provides	symptom relief
TURP	decreases	prostatic obstruction
TURP	bleeding risk	is a complication
TURP	associated with	infection risk
bleeding	is a	complication of TURP
retrograde ejaculation	is a potential outcome of	TURP
catheterization	is used for	postoperative drainage
catheter-associated infection risk	increased with	catheterization
laser enucleation of the prostate	provides	symptom relief
laser enucleation of the prostate	decreases	prostatic obstruction
minimally invasive therapies	used for	BPH management
combination therapy	includes	alpha-blocker plus 5-ARI
alpha-blocker plus 5-ARI	is	combination therapy
trial of medication	is used for	symptom relief
surgical referral	is considered for	refractory symptoms
renal function	monitored with	serum creatinine
PSA testing	is used for	prostate cancer screening
transabdominal ultrasound	used for	prostate size assessment
prostate size	influences	treatment choice
prostate volume	is measured by	ultrasound
digital rectal examination	reveals	prostate enlargement
urinary retention	leads to	catheterization
catheterization	used for	postoperative drainage
catheter-associated infection	risk increased by	catheterization
surgical candidate	evaluated for	comorbidities
anesthesia	is required for	TURP
postoperative analgesia	is required after	TURP
minimally invasive therapies	shorten	hospitalization
operator experience	influences	TURP outcomes
urethral stricture	is a potential complication of	TURP
urinary incontinence	may persist after	TURP
post-void residual	decreases after	treatment
treatment efficacy	varies with	age
surgical technique	influenced by	prostate size
maximal flow rate	improves after	alpha-blocker therapy
PSA levels	may be elevated in	BPH
age	correlates with	BPH severity
alpha-blocker therapy	improves	urinary symptoms
5-alpha-reductase inhibitors	reduce	prostate volume
treatment choice	influenced by	patient age
treatment choice	influenced by	symptom severity
surgical approach	chosen based on	prostate size
reoperation	is possible after	TURP
risk of anesthesia	varies with	TURP
bleeding	may require	transfusion
transfusion	may be necessary for	TURP-associated bleeding
sexual function	preserved after	UroLift
recurrence of obstruction	occurs in	BPH patients
quality of life	improves with	BPH treatment
long-term outcomes	show	symptom stability
